We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UCB Gets FDA Clearance for New Cimzia Indication
UCB Gets FDA Clearance for New Cimzia Indication
May 14, 2009
The FDA has approved UCB’s Cimzia, a tumor necrosis factor (TNF)-alpha blocker, to treat adults with moderately to severely active rheumatoid arthritis (RA).